Overview: What Is PathAI?
PathAI is a digital pathology platform that uses AI to assist anatomic pathologists in primary diagnosis, biomarker quantification, and clinical trial scoring. Founded in 2016 in Boston, PathAI has built the most credentialed regulatory portfolio of any AI pathology vendor: FDA 510(k) clearance for AISight Dx (primary diagnosis with a Predetermined Change Control Plan, the first PCCP for digital pathology), FDA Drug Development Tool Biomarker Qualification for AIM-MASH AI Assist (the first AI pathology tool to receive DDT qualification), and FDA Breakthrough Device Designation for PathAssist Derm.
PathAI's commercial strategy combines lab partnerships (notably the national deployment with Labcorp), pharmaceutical partnerships for clinical trials, and an AI marketplace that hosts third-party algorithms from companies including Mindpeak, Stratipath, and Primaa. This makes PathAI both a software platform and a distribution channel for digital pathology AI.
Key Features
- AISight Dx digital pathology image management system
- AI-powered primary diagnosis for pathologists
- AIM-MASH AI Assist for MASH clinical trials
- PathAssist Derm for dermatopathology
- Whole slide image analysis
- Secure cloud-based slide viewing and management
- Integration with laboratory information systems
- AI model marketplace (Mindpeak, Stratipath, Primaa)
Regulatory & Clinical Validation
PathAI's regulatory portfolio is the strongest case in the AI pathology category. AISight Dx received FDA 510(k) clearance (K243391) for primary diagnosis in June 2025 and was granted a Predetermined Change Control Plan, allowing future model updates without re-clearance for prespecified changes. This is a meaningful regulatory innovation and a sign that the FDA considers PathAI's quality systems mature.
AIM-MASH AI Assist received FDA Drug Development Tool Biomarker Qualification in December 2025 — the first AI pathology tool to be qualified as a DDT. This means the FDA accepts AIM-MASH outputs as valid biomarker measurements in MASH (metabolic dysfunction-associated steatohepatitis) clinical trials, a regulatory recognition that goes well beyond a 510(k) clearance for the specific use case.
PathAssist Derm received FDA Breakthrough Device Designation in March 2026 for dermatopathology, signaling expedited review and engagement with the FDA on a future clearance path.
Pricing
PathAI does not publish standard pricing. Lab and enterprise customers contract on per-case fees, revenue-share arrangements with reference labs, or platform licensing. Pharma clients pay separately for clinical trial partnerships. Practical implication for buyers: budget for a procurement engagement and a multi-month implementation, not a self-serve subscription.
Pros & Cons
Strengths
- ✓ First AI pathology tool with FDA DDT Biomarker Qualification
- ✓ AISight Dx 510(k) cleared for primary diagnosis with PCCP
- ✓ Labcorp national deployment validates production scale
- ✓ AI marketplace hosts third-party pathology algorithms
- ✓ Strong pharma trial partnerships including AIM-MASH
Weaknesses
- ✗ Niche focus — pathology-only, not broad clinical AI
- ✗ Adoption limited by scanner hardware requirements
- ✗ Enterprise-only with complex deployment
- ✗ Most revenue from pharma partnerships, not direct clinical sales
- ✗ Digital pathology market still in early adoption phase
Who Should Evaluate PathAI?
PathAI is built for anatomic pathology labs adopting digital pathology, reference labs serving large case volumes, pharmaceutical companies running MASH or other biomarker-driven trials, and dermatopathology programs evaluating AI assist tools. It is not relevant for non-pathology clinical settings, small practices without whole-slide imaging infrastructure, or organizations evaluating ambient AI scribes or radiology AI.
Verdict
PathAI is the regulatory leader in AI pathology and the right platform to evaluate for any lab serious about digital pathology adoption. The DDT qualification for AIM-MASH is a category-defining regulatory achievement and signals that PathAI is the most likely platform to set FDA precedent for AI pathology going forward. For pharma trial sponsors evaluating MASH biomarker tools, PathAI is currently the only AI option with DDT recognition.